In people with schizophrenia or schizoaffective disorder, 12 weeks of intranasal oxytocin did not significantly improve cognition compared with placebo.
In plain wordsIn people with schizophrenia, oxytocin in the nose did not improve thinking skills more than placebo did.
- Peptide
- Oxytocin
- Outcome
- No significant changeNeurocognition (neuropsychological battery)
- Study
n = 67
- Comparator
- Placebo
- Outcome group
- Cognition and memory · Nervous system and cognition
- Studied dose
- Dose not stated · intranasal · 12 weeksAs given in this study (human).
Source sentences
The results demonstrated that intranasal oxytocin did not significantly improve cognition in people with schizophrenia compared to placebo.
1 context sentence(design, population, supporting numbers)
The current study examined the effect of intranasal oxytocin on cognitive functioning in people with schizophrenia by utilizing data from a 12-week, randomized controlled trial.